☰

Natalia Jura, Ph.D. - Publications

Affiliations: 
SUNY - Stonybrook 
 2011- University of California, San Francisco, San Francisco, CA 
Website:
http://www.cvri.ucsf.edu/~jura/lab/Jura_Lab_Home.html
Tree Info Similar researchers PubMed Report error

56 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 Trenker R, Diwanji D, Bingham T, Verba KA, Jura N. Structural dynamics of the active HER4 and HER2/HER4 complexes is finely tuned by different growth factors and glycosylation. Elife. 12. PMID 38498590 DOI: 10.7554/eLife.92873  0.758
2024 Trenker R, Diwanji D, Bingham T, Verba KA, Jura N. Structural dynamics of the active HER4 and HER2/HER4 complexes is finely tuned by different growth factors and glycosylation. Biorxiv : the Preprint Server For Biology. PMID 38260342 DOI: 10.1101/2023.10.06.561161  0.758
2023 Estevam GO, Linossi EM, Macdonald CB, Espinoza CA, Michaud JM, Coyote-Maestas W, Collisson EA, Jura N, Fraser JS. Conserved regulatory motifs in the juxtamembrane domain and kinase N-lobe revealed through deep mutational scanning of the MET receptor tyrosine kinase domain. Biorxiv : the Preprint Server For Biology. PMID 37577651 DOI: 10.1101/2023.08.03.551866  0.4
2023 Torosyan H, Paul MD, Forget A, Lo M, Diwanji D, Pawłowski K, Krogan NJ, Jura N, Verba KA. Structural insights into regulation of the PEAK3 pseudokinase scaffold by 14-3-3. Nature Communications. 14: 3543. PMID 37336883 DOI: 10.1038/s41467-023-38864-0  0.748
2022 Trenker R, Diwanji D, Verba KA, Jura N. An effective strategy for ligand-mediated pulldown of the HER2/HER3/NRG1β heterocomplex and cryo-EM structure determination at low sample concentrations. Methods in Enzymology. 667: 633-662. PMID 35525557 DOI: 10.1016/bs.mie.2022.03.049  0.776
2022 Diwanji D, Trenker R, Jura N, Verba KA. Efficient expression, purification, and visualization by cryo-EM of unliganded near full-length HER3. Methods in Enzymology. 667: 611-632. PMID 35525556 DOI: 10.1016/bs.mie.2022.03.048  0.751
2022 Diwanji D, Trenker R, Thaker TM, Wang F, Agard DA, Verba KA, Jura N. Author Correction: Structures of the HER2-HER3-NRG1β complex reveal a dynamic dimer interface. Nature. PMID 35132240 DOI: 10.1038/s41586-021-04299-0  0.712
2022 Campbell MR, Ruiz-Saenz A, Peterson E, Agnew C, Ayaz P, Garfinkle S, Littlefield P, Steri V, Oeffinger J, Sampang M, Shan Y, Shaw DE, Jura N, Moasser MM. Targetable HER3 functions driving tumorigenic signaling in HER2-amplified cancers. Cell Reports. 38: 110291. PMID 35108525 DOI: 10.1016/j.celrep.2021.110291  0.307
2021 Diwanji D, Trenker R, Thaker TM, Wang F, Agard DA, Verba KA, Jura N. Structures of the HER2-HER3-NRG1β complex reveal a dynamic dimer interface. Nature. PMID 34759323 DOI: 10.1038/s41586-021-04084-z  0.764
2021 Agnew C, Ayaz P, Kashima R, Loving HS, Ghatpande P, Kung JE, Underbakke ES, Shan Y, Shaw DE, Hata A, Jura N. Structural basis for ALK2/BMPR2 receptor complex signaling through kinase domain oligomerization. Nature Communications. 12: 4950. PMID 34400635 DOI: 10.1038/s41467-021-25248-5  0.398
2021 Verba K, Gupta M, Azumaya C, Moritz M, Pourmal S, Diallo A, Merz G, Jang G, Bouhaddou M, Fossati A, Brilot A, Diwanji D, Hernandez E, Herrera N, Kratochvil H, ... ... Jura N, et al. CryoEM and AI reveal a structure of SARS-CoV-2 Nsp2, a multifunctional protein involved in key host processes. Research Square. PMID 34031651 DOI: 10.21203/rs.3.rs-515215/v1  0.76
2021 Gupta M, Azumaya CM, Moritz M, Pourmal S, Diallo A, Merz GE, Jang G, Bouhaddou M, Fossati A, Brilot AF, Diwanji D, Hernandez E, Herrera N, Kratochvil HT, Lam VL, ... ... Jura N, et al. CryoEM and AI reveal a structure of SARS-CoV-2 Nsp2, a multifunctional protein involved in key host processes. Biorxiv : the Preprint Server For Biology. PMID 34013269 DOI: 10.1101/2021.05.10.443524  0.76
2021 Linossi EM, Estevam GO, Oshima M, Fraser JS, Collisson EA, Jura N. State of the structure address on MET receptor activation by HGF. Biochemical Society Transactions. PMID 33860789 DOI: 10.1042/BST20200394  0.382
2021 Wolpaw AJ, Bayliss R, Büchel G, Dang CV, Eilers M, Gustafson WC, Hansen GM, Jura N, Knapp S, Lemmon MA, Levens D, Maris JM, Marmorstein R, Metallo SJ, Park JR, et al. Drugging the 'undruggable' MYCN oncogenic transcription factor: Overcoming previous obstacles to impact childhood cancers. Cancer Research. PMID 33509943 DOI: 10.1158/0008-5472.CAN-20-3108  0.711
2020 Gordon DE, Hiatt J, Bouhaddou M, Rezelj VV, Ulferts S, Braberg H, Jureka AS, Obernier K, Guo JZ, Batra J, Kaake RM, Weckstein AR, Owens TW, Gupta M, Pourmal S, ... ... Jura N, et al. Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms. Science (New York, N.Y.). PMID 33060197 DOI: 10.1126/science.abe9403  0.738
2020 Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, White KM, O'Meara MJ, Rezelj VV, Guo JZ, Swaney DL, Tummino TA, Huettenhain R, Kaake RM, Richards AL, Tutuncuoglu B, ... ... Jura N, et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. PMID 32353859 DOI: 10.1038/S41586-020-2286-9  0.728
2020 Trenker R, Jura N. Receptor tyrosine kinase activation: From the ligand perspective. Current Opinion in Cell Biology. 63: 174-185. PMID 32114309 DOI: 10.1016/J.Ceb.2020.01.016  0.483
2019 Agnew C, Liu L, Liu S, Xu W, You L, Yeung W, Kannan N, Jablons D, Jura N. The crystal structure of the protein kinase HIPK2 reveals a unique architecture of its CMGC-insert region. The Journal of Biological Chemistry. PMID 31341017 DOI: 10.1074/Jbc.Ra119.009725  0.483
2019 Lopez ML, Lo M, Kung JE, Dudkiewicz M, Jang GM, Von Dollen J, Johnson JR, Krogan NJ, Pawłowski K, Jura N. PEAK3/C19orf35 pseudokinase, a new NFK3 kinase family member, inhibits CrkII through dimerization. Proceedings of the National Academy of Sciences of the United States of America. PMID 31311869 DOI: 10.1073/Pnas.1906360116  0.398
2019 Diwanji D, Thaker T, Jura N. More than the sum of the parts: Toward full-length receptor tyrosine kinase structures. Iubmb Life. PMID 31046201 DOI: 10.1002/Iub.2060  0.529
2019 Kung JE, Jura N. Prospects for pharmacological targeting of pseudokinases. Nature Reviews. Drug Discovery. PMID 30850748 DOI: 10.1038/S41573-019-0018-3  0.463
2019 Kung JE, Jura N. The pseudokinase TRIB1 toggles an intramolecular switch to regulate COP1 nuclear export. The Embo Journal. PMID 30692133 DOI: 10.15252/Embj.201899708  0.382
2019 Ruiz K, Thaker TM, Agnew C, Miller-Vedam L, Trenker R, Herrera C, Ingaramo M, Toso D, Frost A, Jura N. Functional role of PGAM5 multimeric assemblies and their polymerization into filaments. Nature Communications. 10: 531-531. DOI: 10.2210/Pdb6Cni/Pdb  0.358
2018 Pahuja KB, Nguyen TT, Jaiswal BS, Prabhash K, Thaker TM, Senger K, Chaudhuri S, Kljavin NM, Antony A, Phalke S, Kumar P, Mravic M, Stawiski EW, Vargas D, Durinck S, ... ... Jura N, et al. Actionable Activating Oncogenic ERBB2/HER2 Transmembrane and Juxtamembrane Domain Mutations. Cancer Cell. 34: 792-806.e5. PMID 30449325 DOI: 10.1016/J.Ccell.2018.09.010  0.425
2018 Frazier NM, Brand T, Gordan JD, Grandis J, Jura N. Overexpression-mediated activation of MET in the Golgi promotes HER3/ERBB3 phosphorylation. Oncogene. PMID 30390071 DOI: 10.1038/S41388-018-0537-0  0.517
2018 Mishra R, Alanazi S, Yuan L, Solomon T, Thaker TM, Jura N, Garrett JT. Activating HER3 mutations in breast cancer. Oncotarget. 9: 27773-27788. PMID 29963236 DOI: 10.18632/Oncotarget.25576  0.327
2018 Liang SI, van Lengerich B, Eichel K, Cha M, Patterson DM, Yoon TY, von Zastrow M, Jura N, Gartner ZJ. Phosphorylated EGFR Dimers Are Not Sufficient to Activate Ras. Cell Reports. 22: 2593-2600. PMID 29514089 DOI: 10.1016/J.Celrep.2018.02.031  0.409
2018 Liu L, Thaker TM, Freed DM, Frazier N, Malhotra K, Lemmon MA, Jura N. Regulation of Kinase Activity in the Caenorhabditis elegans EGF Receptor, LET-23. Structure (London, England : 1993). PMID 29358026 DOI: 10.1016/J.Str.2017.12.012  0.517
2018 Mishra R, Alanazi S, Yuan L, Solomon T, Thaker TM, Jura N, Garrett JT. Abstract 1896: Patient-derived HER3 mutations transform ER+ and HER2+ breast cancer cells via MAPK pathway activation Cancer Research. 78: 1896-1896. DOI: 10.1158/1538-7445.Am2018-1896  0.396
2017 Neben CL, Lo M, Jura N, Klein OD. Feedback Regulation of RTK Signaling in Development. Developmental Biology. PMID 29079424 DOI: 10.1016/J.Ydbio.2017.10.017  0.344
2017 Agnew C, Jura N. Switching on BTK-One Domain at a Time. Structure (London, England : 1993). 25: 1469-1470. PMID 28978404 DOI: 10.1016/J.Str.2017.09.012  0.426
2017 Littlefield P, Moasser MM, Jura N. Retraction Notice to: An ATP-Competitive Inhibitor Modulates the Allosteric Function of the HER3 Pseudokinase. Cell Chemical Biology. 24: 917. PMID 28732202 DOI: 10.1016/J.Chembiol.2017.07.008  0.307
2017 van Lengerich B, Agnew C, Puchner EM, Huang B, Jura N. EGF and NRG induce phosphorylation of HER3/ERBB3 by EGFR using distinct oligomeric mechanisms. Proceedings of the National Academy of Sciences of the United States of America. PMID 28320942 DOI: 10.1073/Pnas.1617994114  0.458
2016 Kung JE, Jura N. Structural Basis for the Non-catalytic Functions of Protein Kinases. Structure (London, England : 1993). 24: 7-24. PMID 26745528 DOI: 10.1016/J.Str.2015.10.020  0.44
2016 Michael N, Hopkins M, Jura N. Abstract 4590: Mechanism of PI3K activation by the HER3/ErbB3 receptor Cancer Research. 76: 4590-4590. DOI: 10.1158/1538-7445.Am2016-4590  0.464
2015 Michael N, Jura N. Src defines a new pool of EGFR substrates. Nature Structural & Molecular Biology. 22: 945-7. PMID 26643845 DOI: 10.1038/Nsmb.3137  0.429
2015 Kovacs E, Das R, Wang Q, Collier TS, Cantor A, Huang Y, Wong K, Mirza A, Barros T, Grob P, Jura N, Bose R, Kuriyan J. Analysis of the role of the C-terminal tail in the regulation of the epidermal growth factor receptor. Molecular and Cellular Biology. PMID 26124280 DOI: 10.1128/Mcb.00248-15  0.785
2014 Littlefield P, Liu L, Mysore V, Shan Y, Shaw DE, Jura N. Structural analysis of the EGFR/HER3 heterodimer reveals the molecular basis for activating HER3 mutations. Science Signaling. 7: ra114. PMID 25468994 DOI: 10.1126/Scisignal.2005786  0.509
2014 Littlefield P, Moasser MM, Jura N. An ATP-competitive inhibitor modulates the allosteric function of the HER3 pseudokinase. Chemistry & Biology. 21: 453-8. PMID 24656791 DOI: 10.1016/J.Chembiol.2014.02.011  0.501
2014 Murphy JM, Zhang Q, Young SN, Reese ML, Bailey FP, Eyers PA, Ungureanu D, Hammaren H, Silvennoinen O, Varghese LN, Chen K, Tripaydonis A, Jura N, Fukuda K, Qin J, et al. A robust methodology to subclassify pseudokinases based on their nucleotide-binding properties. The Biochemical Journal. 457: 323-34. PMID 24107129 DOI: 10.1042/Bj20131174  0.453
2014 Jura N, Littlefield P, VanHook AM. Science Signaling Podcast: 2 December 2014 Science Signaling. 7: pc31-pc31. DOI: 10.1126/Scisignal.Aaa2963  0.465
2014 Littlefield P, Moasser MM, Jura N. Regulation of the HER3/ErbB3 Pseudokinase Domain by an ATP-Competitive Inhibitor Biophysical Journal. 106: 523a. DOI: 10.1016/J.Bpj.2013.11.2919  0.496
2014 Lengerich Bv, Huang B, Jura N. Single Molecule Imaging of Human Epidermal Growth Factor Receptors Biophysical Journal. 106: 2-9. DOI: 10.1016/J.Bpj.2013.11.1398  0.474
2013 Fan QW, Cheng CK, Gustafson WC, Charron E, Zipper P, Wong RA, Chen J, Lau J, Knobbe-Thomsen C, Weller M, Jura N, Reifenberger G, Shokat KM, Weiss WA. EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma. Cancer Cell. 24: 438-49. PMID 24135280 DOI: 10.1016/J.Ccr.2013.09.004  0.392
2013 Littlefield P, Jura N. EGFR lung cancer mutants get specialized. Proceedings of the National Academy of Sciences of the United States of America. 110: 15169-70. PMID 24023066 DOI: 10.1073/Pnas.1314719110  0.447
2011 Jura N, Zhang X, Endres NF, Seeliger MA, Schindler T, Kuriyan J. Catalytic Control in the EGF Receptor and Its Connection to General Kinase Regulatory Mechanisms Molecular Cell. 42: 9-22. PMID 21474065 DOI: 10.1016/J.Molcel.2011.03.004  0.771
2009 Jura N, Shan Y, Cao X, Shaw DE, Kuriyan J. Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3 Proceedings of the National Academy of Sciences of the United States of America. 106: 21608-21613. PMID 20007378 DOI: 10.1073/Pnas.0912101106  0.666
2009 Jura N, Endres NF, Engel K, Deindl S, Das R, Lamers MH, Wemmer DE, Zhang X, Kuriyan J. Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment. Cell. 137: 1293-307. PMID 19563760 DOI: 10.1016/J.Cell.2009.04.025  0.756
2009 Jura N, Endres NF, Engel K, Deindl S, Das R, Lamers MH, Wemmer DE, Zhang X, Kuriyan J. Mechanism for Activation of the EGF Receptor Catalytic Domain by the Juxtamembrane Segment (DOI:10.1016/j.cell.2009.04.025) Cell. 138: 604. DOI: 10.1016/J.Cell.2009.07.028  0.733
2007 Zhang X, Pickin KA, Bose R, Jura N, Cole PA, Kuriyan J. Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface. Nature. 450: 741-4. PMID 18046415 DOI: 10.1038/Nature05998  0.744
2006 Jura N, Bar-Sagi D. Mapping cellular routes of Ras: a ubiquitin trail. Cell Cycle (Georgetown, Tex.). 5: 2744-7. PMID 17172849 DOI: 10.4161/Cc.5.23.3532  0.511
2006 Archer H, Jura N, Keller J, Jacobson M, Bar-Sagi D. A mouse model of hereditary pancreatitis generated by transgenic expression of R122H trypsinogen. Gastroenterology. 131: 1844-55. PMID 17087933 DOI: 10.1053/J.Gastro.2006.09.049  0.498
2006 Jura N, Scotto-Lavino E, Sobczyk A, Bar-Sagi D. Differential modification of Ras proteins by ubiquitination. Molecular Cell. 21: 679-87. PMID 16507365 DOI: 10.1016/J.Molcel.2006.02.011  0.549
2005 Jura N, Archer H, Bar-Sagi D. Chronic pancreatitis, pancreatic adenocarcinoma and the black box in-between. Cell Research. 15: 72-7. PMID 15686632 DOI: 10.1038/Sj.Cr.7290269  0.483
2003 Kilarski WW, Jura N, Gerwins P. Inactivation of Src family kinases inhibits angiogenesis in vivo: implications for a mechanism involving organization of the actin cytoskeleton. Experimental Cell Research. 291: 70-82. PMID 14597409 DOI: 10.1016/S0014-4827(03)00374-4  0.342
2003 Hall AB, Jura N, DaSilva J, Jang YJ, Gong D, Bar-Sagi D. hSpry2 is targeted to the ubiquitin-dependent proteasome pathway by c-Cbl. Current Biology : Cb. 13: 308-14. PMID 12593796 DOI: 10.1016/S0960-9822(03)00086-1  0.622
Show low-probability matches.